Theraworx® Featured in Four Educational Seminars at the Largest Infection Prevention Conference in the World
Asheville, NC (May 18, 2016) – Avadim Technologies, Inc. (“Avadim”), a life sciences company delivering Pathogenesis Based Therapies (“PBTs”), which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue, announced today that it will launch its new therapy for Incontinence Associated Dermatitis (“IAD”), skin damage associated with exposure to urine or stool, at the 43rd Annual APIC (Association for Professionals in Infection Control and Epidemiology) Conference. Avadim will also host four educational sessions at the Conference focused on its patented Theraworx® products and patent-pending protocols which have demonstrated a proven ability to help hospitals control hospital-acquired conditions.
Stephen Woody, Chairman and CEO, stated, “According to proceedings from Global IAD Expert Panel and published in Wounds International Best Practice Principles, IAD represents a significant health challenge world-wide and is a recognized risk factor in pressure ulcer development. The International consortium calls for new innovative approaches in the treatment of IAD with multiple mechanisms of action. Our formulation closely matches the ‘ideal’ product characteristics. Reports from wound specialists across the country are confirming our belief. In the U.S. alone, it is believed that 70% of the long term care community has fecal and urinary incontinence and 43% have IAD. The incidence in Acute Care is even larger with an estimated total of 3.5 million patients affected in our health system at any one time. The unique mechanism of action of our Theraworx® products optimizes the outer layer of the skin, the Stratum Corneum. We believe that optimizing the permeability barrier by managing the pH is primary to restoring dermal breakdown in patients suffering with IAD. This Pathogenesis-Based Therapy is being recognized by clinical thought leaders nationwide and is rapidly gaining acceptance with Acute Care and Long-Term Care communities.”
Mr. Woody continued, “We will also present educational seminars at the conference on topics including, How our leading clinical product line, Theraworx®, can be your partner eliminating Catheter-Associated Urinary Tract Infections (CAUTI); The story of a journey to ZERO CAUTI through Theraworx® products; A case study of reducing skin infections at a major university wrestling team with Theraworx® bathing protocol; and A Theraworx® operational cost analysis for foley catheter insertion and maintenance. We are looking forward to sharing these exciting new advances with our customers.”
The APIC Conference will be held at the Charlotte Convention Center in Charlotte, N.C. on June 11-13, 2016 and the educational sessions will occur at Avadim’s Theraworx™ booth, number 401. More than 2,500 clinical specialists in Infection Prevention will attend this conference, the largest single annual gathering of this clinical specialty in the United States.
About Theraworx®:
Avadim’s patented Theraworx products and patent-pending protocols have demonstrated a proven ability to help hospitals control hospital-acquired conditions. The unique Theraworx formula helps preserve the body’s natural skin function, by preventing dry skin and helping to maintain the natural acidic, anti-microbial nature of the skin’s outermost layer. For more information on Theraworx®, visit www.theraworx.com
About Avadim Technologies, Inc.:
Avadim Technologies, Inc. is a life sciences company that has developed a new class oflife sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health. For more information on Avadim, visit www.avadimhealth.com
Avadim Technologies Inc. Contacts:
Joe McGuire, Chief Financial Officer
828.251.7111 Office
904.228.2603 Cell
David Fann, President
828.251.7111 Office
904.251.4910 Cell
Investor Relations:
Capital Markets Group, LLC
PH: (914) 669-0222
www.CapMarketsGroup.com